Introduction
Balanced translocations involving the band 11q23 with varying partner chromosomes have been described as subtypespecific abnormalities in several malignant diseases. 1, 2 In nearly all of these aberrations the MLL gene is rearranged with the respective partner gene [3] [4] [5] and the detection of the translocations is correlated with a poor prognosis. [6] [7] [8] [9] The clinical relevance of del(11)(q23), however, is not yet clear. [10] [11] [12] These deletions appear in all age groups and in several types of malignant hematological disease. 13 Two studies showed no involvement of MLL in patients with del(11)(q23) and those patients had a good prognosis. 14, 15 However, others have reported a rearrangement of MLL associated with del(11)(q23). [16] [17] [18] [19] [20] The present study evaluates a large series of patients with del(11)(q23) to discover whether this was associated with specific types of malignant disease, occurred in particular age groups, and whether or not it was associated with a particular prognosis. 
Methods
The method of selection of cases for the Workshop and collection of clinical and laboratory data is described by Secker-Walker (1998). 21 Karyotypes for the following six patients have been published previously: 147, 22 288, 23 375, 24 503, 25 521 and 542.
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Results
From a total of 550 patients 57 had a deletion involving band 11q23. Twenty-seven patients had acute lymphoblastic leukemia (ALL), 16 had acute myeloid leukemia (AML), one had acute biphenotypic leukemia, one had acute undifferentiated leukemia and 12 were diagnosed as having myelodysplastic syndrome (MDS). The latter 12 patients represented nearly half of the MDS cases in this whole study (12 out of 28, 43%).
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Patients with ALL Cytogenetic evaluation showed a pseudodiploid karyotype in most of the patients with ALL ( Table 1) . The deletion was detected as a single abnormality in 9/27 karyotypes whereas 18 patients showed one or more additional aberrations including one with a hyperdiploid (Ͼ50 chromosomes) karyotype. In 15 of the patients the deletion was described as terminal, whereas in the remaining 12 patients interstitial regions of different size were deleted ( Figure 1 classifiable). Most of the patients were found in the group of common or pre-B-ALL, three had a pro-B immunophenotype and four had T-ALL. All clinical data are given in Table 1 . Follow-up was available for all but one patient (patient 600) (see Table 1 ). One infant relapsed at 32.5 months but at 55 months remained in second remission following a bone marrow transplant (BMT). Four of the children relapsed at 11.7, 29.0, 30.1 and 52.8 months, while 6/8 adults had relapsed in under 31 months.
Patients with AML
For the 16 patients with AML the ratio between terminal and interstitial deletions was 10:6 (Table 2) . By FISH analysis, one patient (patient 503) was shown to have an insertion of chromosome 11 material into the other homologue. All six AML patients studied by Southern blotting and/or FISH showed changes of the MLL gene: in 5/6 patients a rearrangement was detected and one patient had lost one allele. Additional chromosomal aberrations were found in half of the patients (8/16). Only two patients were children and one was an infant. Six of the 9 remaining patients were aged 50 years or more. The median age was 23 years (range 4 months to 71 years). The WBC in this group was a median of 50 × 10 9 /l (range 1-221.0 × 10 9 /l). A comparison of FAB types showed that 9/14 classifiable patients were identified as M4/M5 ( Table 2 ). The outcome of AML patients was very poor. For the adults, median event-free survival was 0.5 years (range 4 months to 2.9 years). Both children in this group died after 4 months and 1.2 years (respectively) but the only infant achieved a complete remission and was still alive without relapse after 1 year. One patient with acute biphenotypic leukemia (BIP) aged 54 years and one with acute undifferentiated leukemia (AUL) aged 78 years are included in Table 2 . Both fared poorly. 
Patients with MDS
Seven patients with MDS had an interstitial deletion of 11q and five had a terminal deletion. Additional changes were seen in the stem-line karyotype of nine cases, three being del(5)(q), one being del(7)(q) and one being monosomy 7 (Table 3) . FISH was performed in three patients: one allele of MLL was lost (two cases) and both alleles were retained in the third case. Southern blotting showed germline MLL in one case.
MDS patients were all older than 48 years, median age 69 years (range 49-82 years). The WBC (known for 10 patients) was low, median 3 × 10 9 /l (range 1-14 × 10 9 /l). The most fre- quent FAB type was refractory anemia (RA) seen in seven patients. Five of the MDS patients had died with a median survival of 18.3 months (range 3-22.5 months), whereas the others survived with a median follow-up of 12 months (range 4.4-53.7 months) ( Table 3) .
Discussion
From a large series of 550 patients with 11q23 aberrations, 57 with a deletion of this part of the long arm were analyzed with regard to cytogenetic and clinical features as well as outcome.
Abnormalities of 11q23 commonly comprise balanced translocations and are closely associated with age below 1 year and a high WBC. The blasts are at an early stage of differentiation (pro-B) and the prognosis for all age groups is poor. 6, 7, [28] [29] [30] In contrast, patients with ALL and 11q23 deletions in the present study were mostly aged between 2 and 10 years, had a low WBC and the immunophenotype was pre-B or common ALL. All these are features associated with a good prognosis.
2 Only 4/18 children relapsed and one died. However, two of the three infants with a del(11)(q23) in this study had ALL and in one of them (patient 76) this abnormality was probably due to a complex translocation, involving a t(4;11), as verified by the detection of a MLL/AF4 rearrangement.
Abnormalities involving 11q23 which have been mainly translocations have been reported in a high percentage of infants with AML. 31 In contrast, patients with AML and del(11)(q23) in this series included only one infant (patient 503). This patient also showed a rearrangement of MLL as demonstrated by FISH and Southern blot analysis. 25 Most of the AML patients were adults (12/15) and half were aged 50 years or more. Also in this group the WBC was below 826 50 × 10 9 /l in 7/15 cases which is in contrast to findings in patients with 11q23 translocations. The FAB types M4 and M5, however, also predominated and prognosis was poor. Both children and 11 adults either failed to remit or had relapsed by 18 months. The longest survivor succumbed at 3.8 years following BMT. Four of these patients showed MLL rearrangements.
Deletions of 11q23 are rare events in MDS and the reported incidence ranges between 1 and 5%. 12, 13, 32 Until this workshop little was known about any association of this aberration with clinical features and outcome. In this present series, del(11)(q) correlated with age over 50 years and a low WBC. The FAB type was mainly RA, and in half of the patients the deletion was found together with one of the myeloid associated abnormalities (−5/5q−, −7/7q−, +8).
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In this study, approximately equal numbers of terminal deletions and interstitial deletions of different size were identified. Additional FISH studies in two patients revealed that chromosome 11 was involved in more complex variations than seen by classical cytogenetics. The del(11)(q23) was identified as an apparent sole anomaly in some patients, but in others additional aberrations were present. In two cases of childhood ALL the deletion may have been secondary to t (12;21) or to hyperdiploidy, Ͼ50 chromosomes.
There may be a tendency to assume that all 11q23 aberrations form a uniform group with similar clinical associations. Several authors have shown, however, that in contrast to 11q23 translocations the MLL gene tended not to be involved in deletions. 1, 14, 33 Those authors concluded that examples of deletions with associated MLL gene rearrangement may harbor cryptic translocations. The results of the present study adds support to this argument. When compared with cases with translocations of 11q23, in the Workshop the clinical features of the patients with ALL and deletions were different (infants were rare, WBC was low and immunophenotypes mainly c-and pre-B ALL). Additional studies with FISH revealed complex rearrangements or a translocation involving 11q23.
When considering all these factors it is apparent from the present series that patients with a deletion of 11q23 are genetically heterogeneous and it is difficult to discover any definite clinical associations. However, it is clear that the presence of a del(11)(q23) should be an indication for additional FISH and molecular investigations to exclude a cryptic translocation and to verify or exclude the involvement of the MLL gene. It may then be possible to obtain a clearer picture of the clinical characteristics associated with deletions including the breakpoint 11q23.
